CytoDyn (CYDY)
(Delayed Data from OTC)
$0.16 USD
0.00 (-1.94%)
Updated Sep 23, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for CytoDyn Inc falls in the month of May .
All items in Millions except EPS data.
5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 18 | 41 | 146 | 105 | 75 |
Income After Depreciation & Amortization | -18 | -41 | -145 | -105 | -75 |
Non-Operating Income | -23 | -14 | 4 | -9 | 13 |
Interest Expense | 9 | 25 | 62 | 20 | 18 |
Pretax Income | -50 | -80 | -211 | -155 | -124 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -50 | -80 | -211 | -155 | -124 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -50 | -80 | -211 | -155 | -124 |
Depreciation Footnote | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -29 | -142 | -89 | -71 |
Depreciation & Amortization (Cash Flow) | 2 | 12 | 4 | 16 | 4 |
Income After Depreciation & Amortization | -18 | -41 | -145 | -105 | -75 |
Earnings Per Share Data | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Average Shares | 969.51 | 836.53 | NA | 587.59 | 421.08 |
Diluted EPS Before Non-Recurring Items | -0.05 | -0.10 | NA | -0.25 | -0.21 |
Diluted Net EPS (GAAP) | -0.05 | -0.10 | -0.31 | -0.27 | -0.30 |
Fiscal Year end for CytoDyn Inc falls in the month of May .
All items in Millions except EPS data.
8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.63 | 3.42 | 3.40 | 4.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.63 | -3.42 | -3.40 | -4.61 |
Non-Operating Income | NA | -9.20 | -5.86 | -3.97 | -4.08 |
Interest Expense | NA | 0.95 | 2.65 | 2.20 | 2.88 |
Pretax Income | NA | -16.79 | -11.92 | -9.56 | -11.57 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -16.79 | -11.92 | -9.56 | -11.57 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -16.79 | -11.92 | -9.56 | -11.57 |
Earnings Per Share Data | 8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 999.82 | 982.21 | 958.99 | 923.59 |
Diluted EPS Before Non-Recurring Items | NA | -0.02 | -0.01 | -0.01 | -0.01 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.01 | -0.01 | -0.01 |